Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sivagini Prakash

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Ugeskrift for Laeger|November 5, 2015
[Valproate can induce reversible encephalopathy]Sivagini Prakash, Thomas Harbo, Jakob Christensen
Ugeskrift for Laeger|November 15, 2014
[Valproate can induce reversible encephalopathy]Sivagini Prakash, Thomas Harbo, Jakob Christensen
Journal of Nephrology|November 22, 2022
Focal segmental glomerulosclerosis in a patient with multiple sclerosis treated with Teriflunomide and OcrelizumabAnne-Sofie Greve, Sivagini Prakash, Søren Krag, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 5, 2024
Risk of hypertension in patients with multiple sclerosis treated with teriflunomide compared to dimethyl fumarate: A nationwide cohort study in DenmarkElisabeth Framke, Finn Sellebjerg, Matthias Kant, et al.
Neurology|July 9, 2020
Initial high-efficacy disease-modifying therapy in multiple sclerosis: A nationwide cohort studyMathias Due Buron, Thor Ameri Chalmer, Finn Sellebjerg, et al.
Brain Communications|December 23, 2024
Patterns and predictors of multiple sclerosis phenotype transitionLuigi Pontieri, Nupur Greene, Malthe Faurschou Wandall-Holm, et al.
JAMA Neurology|June 12, 2023
Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple SclerosisIzanne Roos, Stella Hughes, Gavin McDonnell, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Ugeskrift for Laeger|November 5, 2015
[Valproate can induce reversible encephalopathy]Sivagini Prakash, Thomas Harbo, Jakob Christensen
Ugeskrift for Laeger|November 15, 2014
[Valproate can induce reversible encephalopathy]Sivagini Prakash, Thomas Harbo, Jakob Christensen
Journal of Nephrology|November 22, 2022
Focal segmental glomerulosclerosis in a patient with multiple sclerosis treated with Teriflunomide and OcrelizumabAnne-Sofie Greve, Sivagini Prakash, Søren Krag, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 5, 2024
Risk of hypertension in patients with multiple sclerosis treated with teriflunomide compared to dimethyl fumarate: A nationwide cohort study in DenmarkElisabeth Framke, Finn Sellebjerg, Matthias Kant, et al.
Neurology|July 9, 2020
Initial high-efficacy disease-modifying therapy in multiple sclerosis: A nationwide cohort studyMathias Due Buron, Thor Ameri Chalmer, Finn Sellebjerg, et al.
Brain Communications|December 23, 2024
Patterns and predictors of multiple sclerosis phenotype transitionLuigi Pontieri, Nupur Greene, Malthe Faurschou Wandall-Holm, et al.
JAMA Neurology|June 12, 2023
Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple SclerosisIzanne Roos, Stella Hughes, Gavin McDonnell, et al.
Pageof 1